✦ LIBER ✦

Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial)

✍ Scribed by A. N. Boiko; T. T. Batysheva; N. G. Minaeva; L. A. Babina; T. V. Vdovichenko; E. Yu. Zhuravleva; R. K. Shikhkerimov; E. A. Malykhina; A. A. Khozova; K. A. Zaitsev; E. V. Kostenko

Publisher: Springer US
Year: 2008
Tongue: English
Weight: 200 KB
Volume: 38
Category: Article
ISSN: 0097-0549
DOI: 10.1007/s11055-008-9085-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

An open-label evaluation of the tolerabi

An open-label evaluation of the tolerability and safety of Stalevo® (carbidopa, levodopa and entacapone) in Parkinson’s disease patients experiencing wearing-off

✍ W. Koller; M. Guarnieri; J. Hubble; A. L. Rabinowicz; D. Silver 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 80 KB

An open-label, multicentre clinical tria

An open-label, multicentre clinical trial to determine the levodopa dose-sparing capacity of pramipexole in patients with idiopathic Parkinson's disease

✍ M. M. Pinter; A. W. F. Rutgers; E. Hebenstreit; on behalf of the the study cente 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 198 KB

Combining entacapone with levodopa/DDCI

Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson’s Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study

✍ M. Onofrj; A. Thomas; F. Vingerhoets; W. Martin; S. Giménez-Roldán; J.-P. Azulay 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 292 KB